logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The pharmaceutical industry leads the world in R&D investment: it now exceeds 200 billion a year

Aerospace and defence investment is eight times higher than in the aerospace and defence industry, seven times higher than in the chemical industry, and twice as high as in the IT industry.

A report by the International Federation of Pharmaceutical Industries predicts that investment will continue to grow by more than 4% a year in the coming years.

New therapies for hepatitis B and HIV and the development of mRNA technology, some of the most significant advances in the last year

Source: farmaindustria.es

The pharmaceutical industry now spends more than 200 billion euros a year on R&D, making it the industrial sector that spends the most money on research and development in the world. This is highlighted by the International Federation of the Pharmaceutical Industry (Ifpma) in its annual report Facts and Figures 2022: The Pharmaceutical Industry and Global Health, which explains the contribution that this sector makes every year to health, well-being and the global economy.

Specifically, according to the study, pharmaceutical companies dedicated a total of 198,000 million dollars (201,000 million euros at the current exchange rate) to R&D activities in 2020 (the last year with official figures). This amount represents a much higher investment than in other high-tech sectors. The report notes that R&D investment in the pharmaceutical industry is up to 8.1 times higher than that of the aerospace and defence industry, 7.2 times higher than that of the chemical industry and 1.2 times higher than that of software and computer services companies.

Moreover, this investment is sustained over time and growing steadily. The report highlights that global R&D spending in the pharmaceutical sector has grown at an average annual rate of 4.7% between 2012 and 2020 and is forecast to grow at a rate of 4.2% between 2020 and 2026. This projected growth rate will bring the pharmaceutical industry’s R&D investment to $254 billion by 2026, a 28% increase on current investment.

The International Pharmaceutical Industry Federation highlights in the report the reasons why this sector needs to invest so much and for so long in order to obtain results. It points out that the cost of developing a new drug is currently around $2.6 billion and that it is an obstacle course. On average,” the study notes, “researchers identify a promising compound from among 5,000-10,000 selected compounds. Researchers then extensively test the compound to ensure its efficacy and safety, a process that can take 10-15 years for both a drug and a vaccine.

“These data demonstrate that, beyond our role in the fight against Covid-19, the pharmaceutical industry is one of the most innovative sectors in the world and underline our industry’s continued commitment to improving the quality of people’s lives. Our industry is working on innovations that are transforming healthcare and addressing unmet medical needs. Today, our scientists are discovering the new treatments that will transform the lives of future generations,” says Ifpma CEO Thomas Cueni.

More than 3,000 drugs in cancer research

The analysis also highlights some of the fruits of this continued investment in R&D for new medicines. As recently published by the European Federation of the Pharmaceutical Industry (Efpia), there are currently more than 8,000 drugs in clinical trials worldwide, 10% of them for rare diseases. Now, Ifpma details that among the drugs under investigation by the pharmaceutical industry, most are cancer treatments (3,148), followed by drugs in the area of immunology (1,677), neurology (1,668) and infectious diseases (1,488).

In addition to these medicines in development, there are “many promising success stories already in the pipeline,” says the report, which cites the progress made in the past year in the treatment of hepatitis B and HIV as examples. “These new therapies have been shown to eradicate the virus from infected cells, saving patients from lifelong treatment.

Among the latest milestones achieved by the industry, the report also highlights the development of mRNA technology. Decades of trials have led to the development of this new technology that has been instrumental in Covid-19 vaccines and may now be a life-saving therapy for patients with aggressive forms of brain cancer, it notes.

“The future is uncertain, but it will be better for everyone as long as our industry continues to overcome the barriers of science,” says Cueni.

 

 

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.